To improve cancer survivorship and quality of life, it is essential that we improve diagnostic strategies and treatments of a given cancer. Within a tumour, there are molecular differences or heterogeneity that makes standardized treatments challenging. In the past, biomedical research was unidirectional, from lab to bench; every single drug and/or therapy used in the treatment of cancers was developed from fundamental research laboratories dating back to early days of radiotherapy to more modern molecular biology. These therapies have served us well, since treatments based on a few biomarkers did indeed improve survivorship, but certain cancers remain untreatable even today or have a high rate of recurrence. Dr. Marignani created a High Mortality Cancer Precision Medicine Pipeline (P2P) that aims to understand cancer heterogeneity at the single-cell level and establish new solutions for treating high mortality cancers that respond poorly to traditional treatments. Our pipeline brings together stakeholders; scientists, patients, healthcare providers and clinicians. Collectively our expertise include i) gene-discovery that allows for the identification of new biomarkers and therefore new targets; ii) animal models that recapitulate human cancers, and patient-derived xenografts that allow for pre-clinical trials in mouse models to test novel drugs and drug development; iii) immunology and cancer stem cell biology to explore the role the immune system and cancer stem cell niche on tumourigenesis and effective treatment; iv) single-cell fluidics and 3D organ systems that allow for understanding the heterogeneity of cancers; and v) data mining and collaborative assessments that allow for better treatment choices and the discovery of new treatment options based on the molecular biomarkers of each patient’s cancer.